Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.

Paul B ChapmanVetri Sudar JayaprakasamKatherine S PanageasMargaret CallahanMichael A Postow Alexander N ShoushtariJedd D WolchokAllison Betof Warner

Published in: Journal for immunotherapy of cancer (2022)

BOR rate and TTF were markedly less favorable after reinduction with ipi/nivo than after the initial course of ipi/nivo. Reinduction ipi/nivo was associated with frequent irAEs although less frequent than for the initial course.

Keyphrases

end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
risk assessment
human health
patient reported outcomes